Seattle Genetics pockets milestone

A recent INDA from Genentech triggered a milestone payment to Seattle Genetics. In their collaboration, Genentech uses Seattle Genetics' drug conjugates to improve the potency of a therapy. The amount of the milestone was undisclosed. Release

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.